HER2陽性ステージIIIまたはステージIV乳がんの女性に対するエピルビシンとシクロホスファミドに続いてドセタキセルとトラスツズマブを投与する治療法

基本情報

NCT ID

NCT00379015

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

38

治験依頼者名

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

概要

RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy and a monoclonal antibody before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well giving epirubicin and cyclophosphamide followed by docetaxel and trastuzumab works in treating women with HER2-positive stage IIIB, stage IIIC, or stage IV primary breast cancer.

対象疾患

介入

依頼者（Sponsor）

実施施設 (5)